Web1 day ago · Scopus BioPharma Inc. reported earnings results for the full year ended December 31, 2024. For the full year, the company reported net loss was USD 11.61 million compared to USD 26.95 million a year... April 15, 2024 ... Scopus Biopharma Inc. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ... WebJan 19, 2024 · TC BioPharm is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer with human...
TC Biopharm slips on receiving Nasdaq non compliance …
WebDec 17, 2015 · AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. ... Important notice for users Web1 day ago · A complicated legal fight over the Food and Drug Administration’s approval of the abortion pill mifepristone could stifle innovation in the biopharma industry. If courts affirm U.S. District ... irs delay processing paper returns
TC BioPharm Receives Notice of Non-compliance with NASDAQ
WebNov 26, 2024 · Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or. Standard; Transfer of Listing. As previously disclosed on the Current Report on Form 8-K filed on November 29, 2024, First Wave BioPharma, Inc., a Delaware corporation (the "Company"), received a letter (the "Letter") from the Listing Qualifications Department of … WebJan 19, 2024 · TC BioPharm uses an allogeneic approach in both unmodified and CAR modified gamma-delta T cells to effectively identify, target and eradicate both liquid and … WebJan 19, 2024 · TC Biopharm ( NASDAQ: TCBP) has received Nasdaq notice indicating the company has not regained compliance with the rule of $35M minimum market value of … portable underground fence